DOI QR코드

DOI QR Code

Elevated Preoperative Platelet to Lymphocyte Ratio Associated with Decreased Survival of Women with Ovarian Clear Cell Carcinoma

  • Supoken, Amornrat (Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University) ;
  • Kleebkaow, Pilaiwan (Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University) ;
  • Chumworathayi, Bandit (Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University) ;
  • Luanratanakorn, Sanguanchoke (Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University) ;
  • Kietpeerakool, Chumnan (Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University)
  • 발행 : 2015.01.22

초록

This study was conducted to establish whether the preoperative platelet to lymphocyte ratio (PLR) is predictive of survival of women with ovarian clear cell carcinoma (OCCC). A PLR > 300 was deemed elevated. Progression-free survival (PFS) was estimated using the Kaplan-Meier method. Cox proportional hazard analysis was used to determine the independent effect of PLR. Thirty-six patients were reviewed. Elevated PLRs were more commonly noted in patients with an advanced vs an early stage of disease (88.9% vs 11.1%). Women with elevated PLR carried a higher rate of disease progression during primary therapy than that those in the normal PLR group (44.4 vs 22.2%). The median PFS for patients with elevated PLR was notably worse than that for patients with normal PLR (10 vs 34 months). Despite the impact of elevated PLR on PFS, it was found to be marginally significant when controlling for commonly applied prognostic markers. It, however, trended toward significance (HR=4.76; 95%CI, 0.95-23.8). In conclusion, an elevated PLR appears to be directly associated with adverse survival rather than being a surrogate for other indicators of a poor prognosis. PLR may be a useful biomarker for predicting survival of women with OCCC and merits further large-scale studies.

참고문헌

  1. Allensworth SK, Langstraat CL, Martin JR, et al (2013). Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol, 130, 499-504. https://doi.org/10.1016/j.ygyno.2013.05.038
  2. Altman D (1995). Relation between several variables. in: Altman D, editor, practical statistics for medical research. London: chapman & hall. 1995: 325-64.
  3. Asher V, Lee J, Innamaa A, et al (2011). Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol, 13, 499-503. https://doi.org/10.1007/s12094-011-0687-9
  4. Chan JK, Teoh D, Hu JM, et al (2008). Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? a study of 1411 clear cell ovarian cancers. Gynecol Oncol, 109, 370-6. https://doi.org/10.1016/j.ygyno.2008.02.006
  5. Diaz ES, Walts AE, Karlan BY, et al (2013). Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol, 131, 541-5. https://doi.org/10.1016/j.ygyno.2013.09.005
  6. Duska LR, Garrett L, Henretta M, et al (2010). When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol, 116, 374-7. https://doi.org/10.1016/j.ygyno.2009.10.069
  7. Eltabbakh GH, Mount SL, Beatty B, et al (2006). Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol, 93, 379-86. https://doi.org/10.1002/jso.20494
  8. Ertas IE, Gungorduk K, Akman L, et al (2013). Can preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol, 171, 138-42. https://doi.org/10.1016/j.ejogrb.2013.08.023
  9. Halazun KJ, Aldoori A, Malik HZ, et al (2008). Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol, 34, 55-60. https://doi.org/10.1016/j.ejso.2007.02.014
  10. Liu H, Wu Y, Wang Z, et al (2013). Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis, 5, 783-9.
  11. Matsuura Y, Robertson G, Marsden DE, et al (2007). Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol, 104, 406-10. https://doi.org/10.1016/j.ygyno.2006.08.026
  12. Njolstad TS, Engerud H, Werner HM, et al (2013). Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecol Oncol, 131, 410-5. https://doi.org/10.1016/j.ygyno.2013.08.032
  13. Pectasides D, Fountzilas G, Aravantinos G, et al (2006). Advanced stage clear-cell epithelial ovarian cancer: the hellenic cooperative oncology group experience. Gynecol Oncol, 102, 285-91. https://doi.org/10.1016/j.ygyno.2005.12.038
  14. Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, et al (2013). Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev, 14, 2421-7. https://doi.org/10.7314/APJCP.2013.14.4.2421
  15. Prat J (2014). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 124, 1-5. https://doi.org/10.1016/j.ijgo.2013.10.001
  16. Rassouli A, Saliba J, Castano R, et al (2013). Systemic inflammatory markers as independent prognosticators of Head and Neck Squamous cell carcinoma. Head Neck, [Epub ahead of print].
  17. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al (2012). Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol, 23, 265-73. https://doi.org/10.3802/jgo.2012.23.4.265
  18. Recio FO, Piver MS, Hempling RE, et al (1996). Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer, 78, 2157-63. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10<2157::AID-CNCR17>3.0.CO;2-Y
  19. Rustin GJ, Nelstrop AE, McClean P, et al (1996). Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol, 14, 1545-51.
  20. Sirichaisutdhikorn D, Suprasert P, Khunamornpong, S (2009). Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev, 10, 1041-5.
  21. Smith RA, Bosonnet L, Raraty M, et al (2009). Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg, 197, 466-72. https://doi.org/10.1016/j.amjsurg.2007.12.057
  22. Suprasert P, Cheewakriangkrai C, Manopunya M (2012). Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Asian Pac J Cancer Prev, 13, 517-20. https://doi.org/10.7314/APJCP.2012.13.2.517
  23. Surprasert P, Khunamornpong S, Srisomboon J (2006). Clinicopathological features and prognosis of Thai women with endometrioisis-associated ovarian carcinoma. Asian Pac J Cancer Prev, 7, 638-40.
  24. Takano M, Sugiyama T, Yaegashi N, et al (2007). Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol, 12, 256-60. https://doi.org/10.1007/s10147-007-0670-1
  25. Tavassoli FA, Deville P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs.2003.Lyon:IARC Press.
  26. Unal D, Eroglu C, Kurtul N, et al (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  27. Vergote I, Finkler N, del Campo J, et al (2009). Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer, 45, 2324-32. https://doi.org/10.1016/j.ejca.2009.05.016
  28. Wang D, Yang JX, Cao DY, et al (2013). Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther, 6, 211-6.
  29. Wilailak S, Vipupinyo C, Suraseranivong V, et al (2012). Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG, 119, 672-7. https://doi.org/10.1111/j.1471-0528.2012.03298.x
  30. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No 48).Geneva, Switzerland: World Health Organization, 1979.

피인용 문헌

  1. The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3188-6
  2. Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival vol.8, pp.2, 2015, https://doi.org/10.1007/s12254-015-0214-8
  3. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis vol.20, pp.5, 2017, https://doi.org/10.1080/13697137.2017.1326894
  4. Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer vol.60, pp.6, 2017, https://doi.org/10.5468/ogs.2017.60.6.558
  5. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis vol.48, pp.5, 2018, https://doi.org/10.1111/eci.12917